Navigation Links
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
Date:5/5/2009

ct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control and low incidence of hypoglycemia when used with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
6. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
9. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Deutsche Bank 40 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has commenced an underwritten ... expects to grant the underwriters a 30-day option to ... shares of common stock offered in the public offering. ... can be no assurance as to whether or when ...
(Date:4/30/2015)... Paul G. Allen Family Foundation announced today the award ... of researchers with projects at the frontier of one ... human brain cells in the laboratory. The projects are ... years.  "This new cohort of Allen ... the field of neuronal maturation is at the leading ...
(Date:4/30/2015)... Available in select spas in ... , Fleur’s introduces CC CRÈME Perfect ... of makeup, skin care and solar protection in ... designed with specific complexion-correcting pigments to instantly blur ... a healthy glow. Far more than a concealer, ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3
... PAREXEL International,Corporation (Nasdaq: PRXL ) will release ... August 6, 2008 after the close of the stock,market. ... http://www.parexel.com and on the PR Newswire website at ... conference call and live webcast at 10:00 a.m. EDT,on ...
... a leading provider of outsourced CFO-level financial and management services for ... as Partner to its Boston office. Strickland is the latest partner ... last year. , ... Cambridge, MA (PRWEB) July 8, ...
... July 7 American Oriental,Bioengineering, Inc. (NYSE: ... to market conditions and other factors, $85 million ... to qualified,institutional buyers in a private placement exempt ... 1933, as amended (the "Securities,Act")., AOB currently ...
Cached Biology Technology:PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call 2TechCFO Adds Gary Strickland as Partner in Boston Office 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 3
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... 2008 issue of BioScience includes an article by biologist ... on the evolution of advanced social organization in some ... recent evidence that the high level of social organization ... other species), is a result of natural selection on ...
... increase the risk that individuals with cirrhosis of the ... a liver tumor that is the third leading cause ... of the American Medical Association, researchers from Massachusetts General ... finding that a single alteration in the epidermal growth ...
... morning gargle could someday be more than a breath freshener ... at the Johns Hopkins Kimmel Cancer Center. Their new ... to the disease holds promise for screening those at high ... Califano, M.D., says his group at Johns Hopkins asked 211 ...
Cached Biology News:Insects' 'giant leap' reconstructed by founder of sociobiology 2Gene variation may elevate risk of liver tumor in patients with cirrhosis 2Gene variation may elevate risk of liver tumor in patients with cirrhosis 3'Swish-and-spit' test accurate for cancer 2
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
... production demands on cell and tissue culture ... populations. Therefore, both cell concentration and percentage ... and precisely. The new Vi-CELLTM Cell Viability ... means to perform the trypan blue dye ...
... The ProteoExtract™ Protein Precipitation Kit is ... of proteins from aqueous samples. Proteomics ... the presence of non-protein impurities such ... the protein sample that interfere with ...
... series of laser scanners is the starting ... solution. ,Gene expression analysis, SNP (Single ... essential to the advancement of research in ... novel microarray formats and sizes. These arrays ...
Biology Products: